Market Tracker

12/09 5:16pm ET

Vertex Pharmaceuticals Inc (NASDAQ:VRTX)

76.67
Delayed Data
As of 4:00pm ET
 -0.55 / -0.71%
Today’s Change
73.31
Today|||52-Week Range
129.18
-39.07%
Year-to-Date
Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus
Dec 07 / Zacks.com - Paid Partner Content
Nivalis (NVLS) Cystic Fibrosis Study Misses Primary Endpoint
Nov 29 / Zacks.com - Paid Partner Content
The Worst American Stocks of 2016
Dec 07 / MotleyFool.com - Paid Partner Content
Wall Street rallies led by healthcare and banks
Nov 09 / FT.com - Paid Partner Content

Today’s Trading

Previous close77.22
Today’s open77.70
Day’s range76.28 - 79.67
Volume1,618,599
Average volume (3 months)1,719,777
Market cap$19.2B
Dividend yield--
Data as of 4:00pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)+26.43%
Earnings growth (this year)+169.58%
Earnings growth (next 5 years)+46.00%
Revenue growth (last year)+77.86%
P/E ratioNM
Price/Sales29.41
Price/Book20.23

Competitors

 Today’s
change
Today’s
% change
MYLMylan NV+0.45+1.25%
INCYIncyte Corp-2.25-2.19%
BMRNBiomarin Pharmaceuti...-0.83-0.99%
BAXBaxter International...+0.76+1.72%
Data as of 4:14pm ET, 12/09/2016

Financials

Next reporting dateFebruary 1, 2017
EPS forecast (this quarter)$0.27
Annual revenue (last year)$1.0B
Annual profit (last year)-$556.3M
Net profit margin-53.89%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Jeffrey M. Leiden
SVP &
GM-International Commercial Operations
Simon Bedson
Corporate headquarters
Boston, Massachusetts

Forecasts